Aqueous Dispersion Polymerization for the Development of Lamivudine-Polyacrylonitrile Nanoparticles through Quality by Design Approach.

The development of polymeric nanoparticles (NPs) from preformed polymers usually requires the use of organic solvents and is more expensive. Hence, in this work, the development of polymeric nanoparticles by in situ aqueous dispersion polymerization from the monomers was set as an objective. Acrylonitrile monomer based polymeric NPs comprising Lamivudine (LMV) as a model drug were prepared using the aqueous dispersion polymerization technique.

Advancement in the Nose-to-Brain Drug delivery of FDA-approved drugs for the better management of Depression and Psychiatric disorders.

The Prevalence of Depressive and Psychiatric disorders is increasing globally, and despite the availability of numerous FDA-approved drugs, treatment remains challenging. Many conventional antidepressants and antipsychotic formulations face issues such as low solubility, high first-pass metabolism, poor bioavailability, inadequate blood-brain barrier penetration, and systemic side effects. These challenges lead to reduced efficacy, slower onset of action, and decreased patient adherence to treatment.